



May 7, 2015

## **SAGE Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14**

CAMBRIDGE, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2015 at 8:30 a.m. ET to report its financial results for the first quarter 2015 and discuss recent business updates.

The live webcast can be accessed on the investor page of SAGE's website at [investor.sagerx.com](http://investor.sagerx.com). The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 44443636. A replay of the webcast will be available on SAGE's website approximately two hours after the completion of the event.

### **About SAGE Therapeutics**

SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. SAGE's lead program, SAGE-547, is entering Phase 3 clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the Company is developing in its portfolio of potential anti-seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA<sub>A</sub> and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit [www.sagerx.com](http://www.sagerx.com).

CONTACT: Investor Contact:

Paul Cox, SAGE Therapeutics

[paul.cox@sagerx.com](mailto:paul.cox@sagerx.com)

617-299-8377

Media Contact:

Dan Budwick, Pure Communications

[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

973-271-6085



Source: SAGE Therapeutics

News Provided by Acquire Media